FDA’s 27-Year Sunscreen Delay Exposed

The FDA’s approval of bemotrizinol matters because it exposes a simple truth: American sunscreen rules have moved slowly while the rest of the world moved on.

Story Snapshot

Bemotrizinol is a broad-spectrum sunscreen ingredient that the FDA added to the U.S. monograph after a long review ^[2].
The ingredient protects against both ultraviolet A and ultraviolet B rays and has low skin absorption ^[2].
European and other overseas markets have used bemotrizinol for years, which sharpened the pressure on U.S. regulators ^[3].
The FDA says the ingredient is generally recognized as safe and effective for adults and children 6 months and older ^[1].

Why This Approval Took So Long

Bemotrizinol did not get blocked because it lacked promise. The FDA’s own proposal said it gives protection against both ultraviolet A and B rays, has low absorption through the skin, and rarely causes skin irritation ^[2]. Those are strong marks for a sunscreen filter. The real issue was the U.S. system itself, which treats sunscreen actives like over-the-counter drugs and demands a formal safety-and-effectiveness finding before sale ^[2]^[4].

That extra layer of review explains the delay, but it does not erase the frustration. Bemotrizinol had already been used in Europe for decades, and one report noted that Europe approved it in 2000 ^[3]. Public comments and a formal order process also slowed the path in the United States ^[2]. To many consumers, the long wait felt less like caution and more like a regulatory traffic jam that kept a useful tool off store shelves.

What Makes Bemotrizinol Different

Bemotrizinol stands out because it is built for broad protection. ABC News described it as a more stable ultraviolet filter that breaks down less easily in the sun than other filters now on the market ^[1]. That matters because sunscreen that degrades faster can leave skin exposed sooner than people expect. The FDA also said the ingredient has low levels of absorption into the body, which has become a major concern in sunscreen debates ^[2].

That mix of features helps explain why dermatology coverage treated the approval as more than a routine paperwork event ^[5]. Better stability can mean better real-world use, especially for people who spend long hours outdoors. The ingredient also matters because the U.S. sunscreen aisle has been stuck with a narrow set of older choices for years ^[4]^[6]. When the menu is limited, even small upgrades can feel overdue.

What the FDA Is Saying Now

The FDA says it considers bemotrizinol generally recognized as safe and effective for use in sunscreens by adults and children 6 months of age and older ^[1]. It also says the ingredient is a permitted active ingredient now, with the final order guiding when products reach store shelves ^[4]. In plain terms, the agency is not just talking about a future possibility. It has taken the key regulatory step that opens the door.

🚨 Christopher Bunick, MD, PhD, editor in chief of Dermatology Times, shares his insights on yesterday's FDA approval of #bemotrizinol and what the ingredient's properties mean for OTC sun protection and cosmetic elegance.https://t.co/9Pzy3NzmZw #DermTwitter pic.twitter.com/1gWh1rKJ1b

— Dermatology Times (@DermTimesNow) June 10, 2026

The deeper story is bigger than one ingredient. The FDA itself framed this as part of a broader push to advance sunscreen innovation ^[2]. That matters because the United States has spent years trying to modernize a system that still moves slowly compared with Europe and parts of Asia ^[3]^[6]. Bemotrizinol may be the first crack in that wall, but the real test is whether more useful filters follow before another generation grows up waiting.